i.t. MTX/liposomal Ara-C/Tras/Thi (67.3%), surgical derivation (9.8%), WBRT/spinal RT/other RT (27.5%), systemic treatment (71.9%), Anti-HER2 therapy in HER2+ BC (68.8%). Here, ERBB2 is linked to breast cancer.